Unmet needs in psychiatry and emerging novel pharmacological agents

Klinik Psikofarmakoloji Bulteni

Volumn 23, Issue 3, 2013, Pages 199-204

  Cetin, Mesut ^a   Aricioglu, Feyza ^b  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Depression; Drug therapy; Ketamine; Nitroprusside; Sschizophrenia; Treatmentresistant

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANTIDEPRESSANT AGENT; ARGININE; AZD 6765; BITOPERTIN; CALCIUM ION; CEFTRIAXONE; CITRULLINE; CLOZAPINE; DOPAMINE; ESKETAMINE; GLUTAMIC ACID; GLYX 13; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NITROPRUSSIDE SODIUM; NORADRENALIN; PLACEBO; RILUZOLE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL PRACTICE; COGNITIVE DEFECT; DELIRIUM; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EXCITOTOXICITY; HALLUCINATION; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; NERVE CELL PLASTICITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERCEPTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHIATRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SIDE EFFECT; SINGLE DRUG DOSE; VASODILATATION;

EID: 84885030172     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5455/bcp.20130927064824     Document Type: Editorial

References (33)

1. National Institute of Mental Health. Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. http://www. nimh. nih. gov/trials/practical/stard/index. shtml. Accessed April 27, 2012.
2. National Institute of Mental Health. Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). http://www. nimh. nih. gov/trials/practical/step-bd/index. shtml. Accessed April 27, 2012.
3. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry 2006; 59(10): 929-939.
4. Zarate CA Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006; 59(11): 1006-1020.
5. Meldrum BS. Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology. J Nutr 2000; 130: 1007-1015.
6. Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. Glutamatergic Modulators: The Future of Treating Mood Disorders? Harv Rev Psychiatry. 2010; 18(5): 293-303.
7. Miller AH, Maletic V, Raison CL. Inflammation and its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression. Biol Psychiatry 2009; 65: 732-741.
8. Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007; 85(10): 2059-70.
9. Ida T, Hara M, Nakamura Y, Kozaki S, Tsunoda S, Ihara H. Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci Lett 2008; 27; 432(3): 232-6.
10. Pitt D, Nagelmeier IE, Wilson HC, Raine CS. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 2003; 28; 61(8): 1113-20.
11. Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, De Clercq E, et al. A. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001; 4(7): 702-710.
12. Scapagnini G, Davinelli S, Drago F, de Lorenzo A, Oriani G. Antioxidants as antidepressants: fact or fiction? CNS Drugs 2012; 26(6): 477-490.
13. Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Skifter DA, et al. A novel family of negative and positive allosteric modulators of NMDA receptors. J Pharmacol Exp Ther 2010; 335(3): 614-621.
14. Lang UE, Borgwardt S. Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies. Cell Physiol Biochem 2013; 31(6): 761-777.
15. Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochem Pharmacol 2006; 71(9): 1273-1288.
16. Lynch G. Glutamate-based therapeutic approaches: ampakines. Curr Opin Pharmacol 2006; 6(1): 82-88.
17. http://clinicaltrials. gov/ct2/show/NCT00986479
18. http://clinicaltrials. gov/ct2/show/NCT01234558.
19. Brennan BP, Hudson JI, Jensen JE, McCarthy J, Roberts JL, Prescot AP, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010; 35(3): 834-846.
20. Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61(6): 822-825.
21. Chaki S, Ago Y, Palucha-Paniewiera A, Matrisciano F, Pilc A. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 2013; 66: 40-52.
22. Wierońska JM, Pilc A. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem Int 2009; 55(1-3): 85-97.
23. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47(4): 351-354.
24. Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et. al. An open-label trial of the glutamatemodulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005; 57(4): 430-2.
25. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63(8): 856-64.
26. Karolewicz B, Cetin M, Aricioglu F. Beyond the glutamate N-methyl D-aspartate receptor in major depressive disorder: the mTOR signaling pathway. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2011; 21(1): 1-6.
27. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329(5994): 959-64.
28. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012; 62(1): 35-41.
29. Hallak JEC, Oliveira JPM, Abrao J, Evora PR, Zuardi AW, Crippa JA, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 2013; 70(7): 668-676.
30. Dhami K, MacKay M, Maia-de-Oliveira JP, Hallak J, Todd K, Baker G, Dursun S. Novel targets for development of drugs for treating schizophrenia: focus on glycine, d-serine and nitric oxide. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2013; 23(2): 129-37.
31. Jaffrey SR, Snyder SH. Nitric oxide: a neural messenger. Annu Rev Cell Dev Biol 1995; 11: 417-40.
32. Pinkham A, Loughead J, Ruparel K, Wu WC, Overton E, Gur R, et al. Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRI. Psychiatry Res 2011; 194(1): 64-72.
33. http://www. bloomberg. com/news/2013-05-23/j-j-sees-10-products-submitted-for-approval-by-2017. html